188 related articles for article (PubMed ID: 29900015)
61. Apoptotic index by Annexin V flow cytometry: adjunct to morphologic and cytogenetic diagnosis of myelodysplastic syndromes.
Merchant SH; Gonchoroff NJ; Hutchison RE
Cytometry; 2001 Feb; 46(1):28-32. PubMed ID: 11241504
[TBL] [Abstract][Full Text] [Related]
62. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
Götze K; Platzbecker U; Giagounidis A; Haase D; Lübbert M; Aul C; Ganser A; Germing U; Hofmann WK
Ann Hematol; 2010 Sep; 89(9):841-50. PubMed ID: 20567826
[TBL] [Abstract][Full Text] [Related]
63. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies.
Steensma DP; Tefferi A
Leuk Res; 2003 Feb; 27(2):95-120. PubMed ID: 12526916
[TBL] [Abstract][Full Text] [Related]
64. Cold autoimmune hemolytic anemia with myelodysplastic syndrome: Not just an "Open and Shut case".
Mutreja D; Paliwal G; Mangal V; Biswas AK
Indian J Pathol Microbiol; 2022; 65(1):195-197. PubMed ID: 35074995
[TBL] [Abstract][Full Text] [Related]
65. Telomerase activity in myelodysplastic syndromes.
Gürkan E; Tanriverdi K; Başlamişli F
Leuk Res; 2005 Oct; 29(10):1131-9. PubMed ID: 16111531
[TBL] [Abstract][Full Text] [Related]
66. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2011 Jun; 86(6):490-8. PubMed ID: 21594886
[TBL] [Abstract][Full Text] [Related]
67. Classification and prognostic evaluation of myelodysplastic syndromes.
Cazzola M; Della Porta MG; Travaglino E; Malcovati L
Semin Oncol; 2011 Oct; 38(5):627-34. PubMed ID: 21943669
[TBL] [Abstract][Full Text] [Related]
68. Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2018.
Becktell K; Berlyne D; Pagliuca S; Pommert L; Prata PH; Margolis D; de Latour RP; Dufour C; Pierri F
Leuk Res; 2019 May; 80():19-25. PubMed ID: 30908982
[TBL] [Abstract][Full Text] [Related]
69. When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis.
Bonadies N; Rovó A; Porret N; Bacher U
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801484
[TBL] [Abstract][Full Text] [Related]
70. Aging, hematopoiesis, and the myelodysplastic syndromes.
Chung SS; Park CY
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):73-78. PubMed ID: 29222239
[TBL] [Abstract][Full Text] [Related]
71. Deep learning application of the discrimination of bone marrow aspiration cells in patients with myelodysplastic syndromes.
Lee N; Jeong S; Park MJ; Song W
Sci Rep; 2022 Nov; 12(1):18677. PubMed ID: 36333407
[TBL] [Abstract][Full Text] [Related]
72. [Sternal bone marrow cell morphology evaluation utility for diagnostic categorization in patients with acquired hypocellular bone marrow failure syndromes].
Chen J; Qin TJ; Qu SQ; Pan LJ; Zhang PH; Li B; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2022 Nov; 43(11):928-933. PubMed ID: 36709184
[No Abstract] [Full Text] [Related]
73. [Perspective on the treatment of myelodysplastic syndromes].
Tohyama K
Nihon Rinsho; 2011 Dec; 69(12):2257-66. PubMed ID: 22242330
[TBL] [Abstract][Full Text] [Related]
74. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
Tauro S; Hepburn MD; Bowen DT; Pippard MJ
Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
[TBL] [Abstract][Full Text] [Related]
75. PAS positivity of erythroid precursor cells is associated with a poor prognosis in newly diagnosed myelodysplastic syndrome patients.
Masuda K; Shiga S; Kawabata H; Takaori-Kondo A; Ichiyama S; Kamikubo Y
Int J Hematol; 2018 Jul; 108(1):30-38. PubMed ID: 29600427
[TBL] [Abstract][Full Text] [Related]
76. [Myelodysplastic syndromes: pathophysiology, clinical and biological features].
Becha M; Braham Jmili N
Ann Biol Clin (Paris); 2015; 73(6):643-56. PubMed ID: 26635046
[TBL] [Abstract][Full Text] [Related]
77. Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes.
Navada SC; Silverman LR
Ther Adv Hematol; 2017 Jan; 8(1):21-27. PubMed ID: 28042456
[TBL] [Abstract][Full Text] [Related]
78. The functional interplay of transcription factors and cell adhesion molecules in experimental myelodysplasia including hematopoietic stem progenitor compartment.
Daw S; Law S
Mol Cell Biochem; 2021 Feb; 476(2):535-551. PubMed ID: 33011884
[TBL] [Abstract][Full Text] [Related]
79. Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells.
Luo B; Dong F; Qin T; Zhang Q; Bai H; Wang J; Jia Y; Ma S; Jiang E; Cheng T; Xiao Z; Ema H
Exp Hematol Oncol; 2022 May; 11(1):28. PubMed ID: 35578364
[TBL] [Abstract][Full Text] [Related]
80. Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome.
Sato T; Kim S; Selleri C; Young NS; Maciejewski JP
Leukemia; 1998 Aug; 12(8):1187-94. PubMed ID: 9697872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
